Supernus Pharmaceuticals-Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Supernus Pharmaceuticals reported $149.82 million in revenue for Q1 2025, a year-over-year increase of 4.3% and a surprise of +2.91% over the Zacks Consensus Estimate of$ 145.59 million [1] - The company achieved an EPS of $0.42, compared to$ 0.00 a year ago, with an EPS surprise of +10.53% against the consensus estimate of $0.38 [1] Revenue Breakdown - Trokendi XR generated$ 12.80 million in net product sales, exceeding the average estimate of $8.58 million, but representing a year-over-year decline of -20% [4] - Oxtellar XR reported$ 10.20 million in net product sales, below the average estimate of $12.29 million, with a significant year-over-year decrease of -62.1% [4] - Qelbree achieved$ 64.70 million in net product sales, slightly below the average estimate of $65.54 million, but showing a year-over-year increase of +43.5% [4] - Total net product sales amounted to$ 141.99 million, surpassing the average estimate of $140.61 million, reflecting a year-over-year growth of +2.6% [4] - Royalty revenues reached$ 7.84 million, exceeding the estimated $5.80 million, with a year-over-year increase of +51.2% [4] - GOCOVRI net product sales were$ 30.70 million, above the average estimate of $30.13 million, marking a year-over-year increase of +15.9% [4] - Other net product sales totaled$ 8.60 million, surpassing the average estimate of $7.38 million, with a year-over-year growth of +19.4% [4] - APOKYN reported$ 15 million in net product sales, below the average estimate of $16.70 million, reflecting a year-over-year decline of -10.2% [4] Stock Performance - Supernus shares returned +0.4% over the past month, while the Zacks S&P 500 composite increased by +11.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance against the broader market in the near term [3]